Related Experiment Video
Updated: Aug 10, 2026
11:36
A RAPID Method for Blood Processing to Increase the Yield of Plasma Peptide Levels in Human Blood
Published on: April 28, 2016
Incretin hormones--an update
1Department of Medical Physiology, The Panum Institute, University of Copenhagen, Denmark. holst@mfi.ku.dk
Summary
Incretin hormones like GLP-1 enhance insulin secretion and are impaired in type 2 diabetes. Therapeutic GLP-1 administration shows promise for normalizing blood sugar and potentially regenerating beta cells.
Area of Science:
- Endocrinology
- Gastroenterology
- Metabolic Diseases
Background:
- Incretin hormones, including GIP and GLP-1, are released post-meal and enhance glucose-stimulated insulin secretion.
- Incretin function is crucial for glucose homeostasis and is significantly impaired in type 2 diabetes mellitus.
- Impairment involves reduced GLP-1 secretion and diminished GIP insulinotropic effects in T2DM patients.
Purpose of the Study:
- To investigate the role of incretin hormones in glucose metabolism.
- To explore the therapeutic potential of GLP-1 for type 2 diabetes treatment.
Main Methods:
- Review of existing literature on incretin physiology and type 2 diabetes.
- Analysis of GLP-1 administration effects in preclinical models and human studies.
Main Results:
- GLP-1 administration in type 2 diabetes patients can normalize fasting and postprandial hyperglycemia.
- GLP-1 demonstrates potential for stimulating beta-cell proliferation and differentiation in rodents.
- GLP-1 exhibits additional benefits including glucagon inhibition, delayed gastric emptying, and appetite reduction.
Conclusions:
- GLP-1 is a key incretin hormone with significant therapeutic potential for type 2 diabetes.
- Targeting the incretin system, particularly with GLP-1, offers a promising avenue for managing type 2 diabetes.
- Further development of GLP-1-based therapies is warranted for clinical application in type 2 diabetes.
More Related Videos
09:16Mixed Primary Cultures of Murine Small Intestine Intended for the Study of Gut Hormone Secretion and Live Cell Imaging of Enteroendocrine Cells
Published on: April 20, 2017
07:00Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine
Published on: February 26, 2019
Related Concept Videos
01:40Hormonal Regulation
Hormones regulate a significant portion of digestion through activation of the neuroendocrine system. The neuroendocrine system of digestion contains many different hormones all with multiple functions that are both, directly and indirectly, involved in digestion.
01:05Insulin Secretory Vesicles
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
01:16Hormones Regulating Blood Glucose
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...
Insulin and C-peptide are co-secreted in...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...